Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Non-Current Debt (2020 - 2022)

Historic Non-Current Debt for SAB Biotherapeutics (SABS) over the last 2 years, with Q4 2022 value amounting to $541644.0.

  • SAB Biotherapeutics' Non-Current Debt changed N/A to $541644.0 in Q4 2022 from the same period last year, while for Dec 2022 it was $541644.0, marking a year-over-year change of. This contributed to the annual value of $541644.0 for FY2022, which is N/A changed from last year.
  • Per SAB Biotherapeutics' latest filing, its Non-Current Debt stood at $541644.0 for Q4 2022.
  • SAB Biotherapeutics' 5-year Non-Current Debt high stood at $541644.0 for Q4 2022, and its period low was $172037.0 during Q4 2020.